Evidence-based dosing of convalescent plasma for COVID-19 in future trials

BACKGROUND: Two years into the pandemic, convincing evidence in favour of convalescent plasma (ConvP) as a treatment for coronavirus disease 2019 (COVID-19) is still lacking. This contrasts sharply with the efficacy of potent virus-neutralizing monoclonal antibodies. However, resistance of the Omicr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rijnders, Bart J.A., Huygens, Sammy, Mitjà, Oriol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828382/
https://www.ncbi.nlm.nih.gov/pubmed/35150881
http://dx.doi.org/10.1016/j.cmi.2022.01.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828382/
https://www.ncbi.nlm.nih.gov/pubmed/35150881
http://dx.doi.org/10.1016/j.cmi.2022.01.026

Ejemplares similares